Aspire Biopharma Holdings, Inc.
ASBP
NASDAQ·Consumer Cyclical·Auto - Parts·Mkt cap $1.0M
$8.70
▼ -0.68%
P/E
-1.08
Mkt Cap
$1.0M
52-Wk Range
$0.11–$562.80
52-Week Range
$0.11 - $562.80
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 98.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary sublingual delivery technology platform
- First-mover advantage in rapid-absorption aspirin formulation
- Diverse pipeline reducing single-product risk
- Potential for rapid commercialization across multiple therapeutic categories
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
No forward estimates available
Commercialization and market adoption of Instaprin in cardiology and pain management
Value
Valuation data unavailable
Momentum
Hot
+56.1% over 3m
Quality
Thin
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ASBP right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
AUG 13, 2026
Most recent quarter reported revenue of $63.1K. Reported EPS of -$1.22. Gross margin -47.7%.
Reported EPS · last 4Q
0 of 1 beats
Q3 26
—
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$1.9K
$4.3K
$28.4K
$63.1K
Margins · last 8Q
Gross
-47.7%
Profit
-2009.6%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How ASBP stacks vs Auto - Parts
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related